NCT03606746View on ClinicalTrials.gov

Cellular Immunotherapy for Immune Tolerance in Past Recipients of HLA Zero-mismatch, Living Donor Kidney Transplants

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

December 31, 2024

Primary Completion Date

August 31, 2025

Study Completion Date

October 31, 2025

Conditions
Kidney Transplant Rejection
Interventions
BIOLOGICAL

MDR-103

MDR-103 Enriched CD34+ hematopoietic stem cells and defined dose of CD3+ T-cells

Sponsors
All Listed Sponsors
lead

Medeor Therapeutics, Inc.

INDUSTRY